article · The Journal of Immunology
Fast-evolving MHC class I polymorphism serves to diversify NK cell and CD8 T cell responses in individuals, families, and populations. Because only chimpanzee and bonobo have strict orthologs of all <i>HLA class I</i>, their study gives unique perspectives on the human condition. We defined polymorphism of <i>Papa-B</i>, the bonobo ortholog of <i>HLA-B</i>, for six wild bonobo populations. Sequences for <i>Papa-B</i> exon 2 and 3 were determined from the genomic DNA in 255 fecal samples, minimally representing 110 individuals. Twenty-two <i>Papa-B</i> alleles were defined, each encoding a different Papa-B protein. No Papa-B is identical to any chimpanzee Patr-B, human HLA-B, or gorilla Gogo-B. Phylogenetic analysis identified a clade of MHC-B, defined by residues 45-74 of the α<sub>1</sub> domain, which is broadly conserved among bonobo, chimpanzee, and gorilla. Bonobo populations have 3-14 Papa-B allotypes. Three Papa-B are in all populations, and they are each of a different functional type: allotypes having the Bw4 epitope recognized by killer cell Ig-like receptors of NK cells, allotypes having the C1 epitope also recognized by killer cell Ig-like receptors, and allotypes having neither epitope. For population Malebo, these three Papa-B are the only Papa-B allotypes. Although small in number, their sequence divergence is such that the nucleotide diversity (mean proportional distance) of <i>Papa-B</i> in Malebo is greater than in the other populations and is also greater than expected for random combinations of three <i>Papa-B</i> Overall, <i>Papa-B</i> has substantially less diversity than <i>Patr-B</i> in chimpanzee subspecies and <i>HLA-B</i> in indigenous human populations, consistent with bonobo having experienced narrower population bottlenecks.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4049/jimmunol.1601955
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.